We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+9.16%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$5.79B
AUM Growth
+$493M
(+9.3%)
Cap. Flow
+$186M
Cap. Flow
% of AUM
3.21%
Top 10 Holdings %
Top 10 Hldgs %
23.53%
Holding
286
New
43
Increased
91
Reduced
94
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$52.9M |
| 2 |
Canadian Natural Resources
CNQ
|
+$43.8M |
| 3 |
Abbott
ABT
|
+$37.3M |
| 4 |
Amgen
AMGN
|
+$35M |
| 5 |
Ametek
AME
|
+$28.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$66.2M |
| 2 |
N
Netsuite Inc
N
|
+$40M |
| 3 |
AGN
Allergan plc
AGN
|
+$39.6M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$38.9M |
| 5 |
BCR
CR Bard Inc.
BCR
|
+$33.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.6% |
| 2 | Healthcare | 21.19% |
| 3 | Financials | 20.46% |
| 4 | Communication Services | 9.97% |
| 5 | Consumer Discretionary | 5.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TRIL
226
DELISTED
Trillium Therapeutics Inc.
TRIL
| $488K | 0.01% |
+33,000
| New | +$380K |
|
227
Citizens Financial Group
CFG
$30.1B
| $438K | 0.01% |
17,707
-7,087
| -29% | -$163K |
|
|
OPB
228
DELISTED
Opus Bank Common Stock
OPB
| $427K | 0.01% |
12,059
+2,256
| +23% | +$77.1K |
|
|
ADAP
229
DELISTED
Adaptimmune Therapeutics
ADAP
| $423K | 0.01% |
60,000
+10,000
| +20% | +$76.3K |
|
|
NVTA
230
DELISTED
Invitae Corporation
NVTA
| $416K | 0.01% |
47,500
-7,500
| -14% | -$63.1K |
|
231
Coherus Oncology
CHRS
$225M
| $402K | 0.01% |
+15,000
| New | +$409K |
|
232
Ocular Therapeutix
OCUL
$1.89B
| $395K | 0.01% |
57,500
-17,373
| -23% | -$106K |
|
233
Acadia Pharmaceuticals
ACAD
$4.35B
| $358K | 0.01% |
11,250
-19,143
| -63% | -$649K |
|
|
ISEE
234
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $334K | 0.01% |
7,250
-35,826
| -83% | -$2.02M |
|
235
KeyCorp
KEY
$24.1B
| $324K | 0.01% |
+26,663
| New | +$319K |
|
|
HSTO
236
DELISTED
Histogen Inc. Common Stock
HSTO
| $311K | 0.01% |
783
| – | – |
|
237
iShares MSCI Emerging Markets ETF
EEM
$28.6B
| $253K | ﹤0.01% |
+6,762
| New | +$247K |
|
238
TSMC
TSM
$2.07T
| $203K | ﹤0.01% |
+6,640
| New | +$190K |
|
239
Alcoa
AA
$11.6B
| – | – |
-36,457
| Closed | -$812K |
|
240
Acadia Healthcare
ACHC
$2.99B
| – | – |
-330,000
| Closed | -$18.3M |
|
241
Alamos Gold
AGI
$12.5B
| – | – |
-325,000
| Closed | -$2.72M |
|
242
Align Technology
ALGN
$12B
| – | – |
-120,000
| Closed | -$9.67M |
|
243
Alkermes
ALKS
$8.79B
| – | – |
-7,852
| Closed | -$339K |
|
244
Check Point Software Technologies
CHKP
$13.6B
| – | – |
-38,000
| Closed | -$3.03M |
|
|
DVAX
245
DELISTED
Dynavax Technologies
DVAX
| – | – |
-379,932
| Closed | -$5.54M |
|
246
DexCom
DXCM
$28.3B
| – | – |
-60,652
| Closed | -$1.2M |
|
247
Hecla Mining
HL
$10.2B
| – | – |
-770,000
| Closed | -$3.8M |
|
248
Inogen
INGN
$171M
| – | – |
-193,524
| Closed | -$9.7M |
|
249
Standard BioTools
LAB
$303M
| – | – |
-54,132
| Closed | -$489K |
|
250
Altria Group
MO
$122B
| – | – |
-15,500
| Closed | -$1.07M |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q3 2016 Portfolio in Review
As of Q3 2016, Polar Capital held 286 positions worth $5.79B, up 9.3% from $5.3B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Polar Capital deployed $186M of net new capital in Q3 2016, opening 43 new positions and adding to 91 existing holdings. Its largest new stake was Canadian Natural Resources: 2,876,960 shares worth $52.7M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 21% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Pfizer, an estimated $66.2M trimmed.
- Polar Capital's largest Q3 2016 buy was Canadian Natural Resources: 2,876,960 shares worth $52.7M.
- Polar Capital added most to Merck in Q3 2016, an estimated $52.9M increase.
- Polar Capital's biggest Q3 2016 reduction was Pfizer, cutting an estimated $66.2M.
- Polar Capital fully exited Allergan plc in Q3 2016, selling an estimated $39.6M.
- Polar Capital's ten largest holdings make up 24% of its $5.79B portfolio in Q3 2016.
- Polar Capital opened 43 new positions and closed 31 in Q3 2016.
- Polar Capital's portfolio value rose 9.3% quarter-over-quarter to $5.79B.
Based on Polar Capital's 13F filing for Q3 2016, filed 14 Nov 2016.